de Béthune MP - Search Results

1

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Madruga JV, et al. Among authors: de bethune mp, de pauw m. Lancet. 2007 Jul 7;370(9581):49-58. doi: 10.1016/S0140-6736(07)61049-6. Lancet. 2007. PMID: 17617272 Clinical Trial.

2

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP. De Meyer S, et al. Among authors: de bethune mp, de paepe e. AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec. AIDS. 2009. PMID: 19474650 Clinical Trial.

3

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD. De Meyer SM, et al. Among authors: de bethune mp. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):179-82. doi: 10.1097/QAI.0b013e318183a959. J Acquir Immune Defic Syndr. 2008. PMID: 18769351 Clinical Trial.

4

Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

Pozniak A, Opravil M, Beatty G, Hill A, de Béthune MP, Lefebvre E. Pozniak A, et al. Among authors: de bethune mp. AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80. doi: 10.1089/aid.2007.0275. AIDS Res Hum Retroviruses. 2008. PMID: 18844462 Clinical Trial.

5

Resistance profile of darunavir: combined 24-week results from the POWER trials.

de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP. de Meyer S, et al. Among authors: de bethune mp, de paepe e. AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88. doi: 10.1089/aid.2007.0173. AIDS Res Hum Retroviruses. 2008. PMID: 18327986 Clinical Trial.

6

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Béthune MP, Picchio G. Dierynck I, et al. Among authors: de bethune mp. Antivir Ther. 2010;15(8):1161-9. doi: 10.3851/IMP1697. Antivir Ther. 2010. PMID: 21149923 Clinical Trial.

7

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.

Cohen CJ, Berger DS, Blick G, Grossman HA, Jayaweera DT, Shalit P, Thompson M, Peeters M, de Béthune MP, Voorspoels E, Mack R, Woodfall B. Cohen CJ, et al. Among authors: de bethune mp. AIDS. 2009 Jan 28;23(3):423-6. doi: 10.1097/QAD.0b013e32831c5040. AIDS. 2009. PMID: 19114852 Clinical Trial.

8

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G. Lathouwers E, et al. Among authors: de bethune mp. Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719. Antivir Ther. 2011. PMID: 21311113 Clinical Trial.

9

Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".

Picchio G, De Meyer S, de Béthune MP. Picchio G, et al. Among authors: de bethune mp, de meyer s. AIDS. 2008 Jan 2;22(1):165-7. doi: 10.1097/QAD.0b013e3282f2be42. AIDS. 2008. PMID: 18090413 Review. No abstract available.

10

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

De Meyer S, Hill A, Picchio G, DeMasi R, De Paepe E, de Béthune MP. De Meyer S, et al. Among authors: de bethune mp, de paepe e. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):563-4. doi: 10.1097/QAI.0b013e318183ac9c. J Acquir Immune Defic Syndr. 2008. PMID: 19202459 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page